ADMA Biologics is trading 6.13% down at $10.71 ahead of the November 2, 2026 market open. No clear company-specific announcement explaining the decline surfaced in available coverage, and the reason remains unclear.
- Major U.S. indices are higher, so the broader market context does not explain the opposite-direction move.
- ADMA Biologics is scheduled to report third-quarter results on November 4, after market close; the upcoming report does not establish a cause for this morning’s decline.